Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Kluczowe dokumenty

421M-1

Sigma-Aldrich

p21WAF1 (DCS-60.2) Mouse Monoclonal Antibody

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Kod UNSPSC:
12352203
NACRES:
NA.41

pochodzenie biologiczne

mouse

Poziom jakości

100
500

białko sprzężone

unconjugated

forma przeciwciała

diluted ascites fluid

rodzaj przeciwciała

primary antibodies

klon

DCS-60.2, monoclonal

opis

For In Vitro Diagnostic Use in Select Regions (See Chart)

Formularz

buffered aqueous solution

reaktywność gatunkowa

human

opakowanie

vial of 0.1 mL concentrate (421M-14)
vial of 0.5 mL concentrate (421M-15)
bottle of 1.0 mL predilute (421M-17)
vial of 1.0 mL concentrate (421M-16)
bottle of 7.0 mL predilute (421M-18)

producent / nazwa handlowa

Cell Marque®

metody

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:50-1:200

izotyp

IgG2a

kontrola

colon

Warunki transportu

wet ice

temp. przechowywania

2-8°C

wizualizacja

nuclear

informacje o genach

human ... CDKN1A(1026)

Opis ogólny

p21 is a nuclear 21 kD protein, a product of the WAF1/CIP1 gene. It is a cyclin-dependent kinase inhibitor 1A (p21, Cip1), also known as CDKN1A, which in humans is encoded by the CDKN1A gene located on chromosome (6p21.2). It is a constituent of a large complex of nuclear proteins, including cyclins, cyclin dependent kinases, and PCNA. Cell cycle progression is regulated by cyclins and their cognate Cdks. p21 inhibits the activity of each member of the cyclin/Cdk family. The expression of this gene acts as an inhibitor of the cell cycle during G1 phase and is tightly controlled by the tumor suppressor protein p53. Normal cells generally display a rather intense nuclear p21 expression. Loss of p21 expression has been reported in many carcinomas (gastric carcinoma, non-small cell lung carcinoma, thyroid carcinoma).

Jakość


IVD

IVD

IVD

RUO

Powiązanie

p21WAF1 Positive Control Slides, Product No. 421S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Postać fizyczna

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Uwaga dotycząca przygotowania

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Inne uwagi

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Informacje prawne

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
Ta strona może zawierać tekst przetłumaczony maszynowo.

Nie możesz znaleźć właściwego produktu?  

Wypróbuj nasz Narzędzie selektora produktów.


Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

Nie widzisz odpowiedniej wersji?

Jeśli potrzebujesz konkretnej wersji, możesz wyszukać konkretny certyfikat według numeru partii lub serii.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

M Ikeguchi et al.
Digestive diseases and sciences, 43(5), 964-970 (1998-05-20)
To evaluate whether the expression of p53 and that of p21 are independent prognostic factors in patients with advanced gastric cancer, we investigated clinicopathological factors and the expression of p53 and p21 in 158 patients with gastric cancer that had
Jinyoung Yoo et al.
Journal of Korean medical science, 22(2), 318-325 (2007-04-24)
Non-small cell lung cancers (NSCLC) vary in their biologic behavior. Recurrence and tumor-related mortality may be attributable to molecular abnormalities in primary tumors. This study evaluated such immunophenotypes with regard to cell cycle regulation and proliferation, apoptosis, and angiogenesis, to
J A DiGiuseppe et al.
The American journal of pathology, 147(4), 884-888 (1995-10-01)
The p53 tumor suppressor gene is mutated in the majority of pancreatic adenocarcinomas, and several studies have suggested that loss of p53 function may contribute to the aggressive clinical behavior of pancreas cancer. Although immunocytochemical accumulation of the p53 gene
Mi Seon Kwon et al.
Pathology, research and practice, 202(12), 849-856 (2006-11-04)
Few studies have focused on the correlation between p21 expression and survival for patients with non-small cell lung carcinoma (NSCLC), and the results are not consistent. We investigated the expression of p21 in 90 cases of NSCLC to evaluate the
Motohiko Tamura et al.
Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 13(1), 9-14 (2007-03-30)
The prognostic value of p21 protein expression in lung cancer patients has been assessed. However, its significance in those with pulmonary squamous cell carcinoma following induction chemotherapy (IC) remains unclear. We studied on patients who did or did not undergo

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej